INSM — Insmed Incorporated stock price, charts and financials

QT56Insmed Incorporated

Insmed Incorporated (NASDAQ: INSM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
133.23
+2.13+1.63%
OverviewShort InterestFilings
INSMQT56Insmed Incorporated·NASDAQ
133.23+1.63%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ALNY-0.35%$218.42ROIV-0.78%$36.06INCY+1.24%$122.05MRNA+0.54%$59.49BNTX-0.15%$93.53UTHR-1.83%$528.97GMAB-1.20%$30.88RVMD+0.24%$205.64
Snapshot
Index-P/E-EPS (ttm)-5.75Insider Own1.00%Shs Outstand216.75MPerf Week32.96%
Market Cap28.42BForward P/E-EPS next Y0.33Insider Trans-19.17%Shs Float198.42MPerf Month10.86%
Enterprise Value27.91BPEG-EPS next Q-Inst Own-Short Float5.86%Perf Quarter24.86%
Income-872.38MP/S24.98EPS this Y54.60%Inst Trans-Short Ratio3.09Perf Half Y-13.20%
Sales1.14BP/B37.62EPS next Y112.75%ROA-41.63%Short Interest11.62MPerf YTD-24.67%
Book/sh-P/C-EPS next 5Y-ROE-111.26%52W High216.22 -38.38%Perf Year17.83%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-48.85%52W Low91.86 45.04%Perf 3Y502.20%
Dividend Est.-EV/EBITDA-Sales past 3/5Y35.24% 29.88%Gross Margin83.27%Volatility5.22% 4.00%Perf 5Y432.93%
Dividend TTM-EV/Sales24.53EPS Y/Y TTM-3.23%Oper. Margin-71.86%ATR (14)6.50Perf 10Y1057.11%
Dividend Ex-Date-Quick Ratio3.40Sales Y/Y TTM125.00%Profit Margin-76.94%RSI (14)73.74Recom2.09
Dividend Gr. 3/5Y-Current Ratio3.72EPS Q/Q46.48%SMA2021.76%Beta0.85Target Price196.71
Payout0.00%Debt/Eq0.05Sales Q/Q229.03%SMA5024.50%Rel Volume1.22Prev Close131.10
Employees1,664LT Debt/Eq1.01EarningsOct 29SMA200-10.39%Avg Volume4.02MPrice133.23
IPO DateJun 01, 2000Option/ShortYes / YesEPS/Sales Surpr.21.11% 1.71%Net Debt/EBITDA0.66Volume4,901,026Change1.63%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedMorgan StanleyOverweight$212 → $218
Aug-07-26ReiteratedEvercore ISIOutperform$160 → $170
Aug-07-26ReiteratedGuggenheimBuy$207 → $205
Aug-07-26ReiteratedUBSBuy$166 → $172
Aug-07-26ReiteratedWells FargoOverweight$161 → $169
Aug-06-26ReiteratedJefferiesBuy$160 → $175
Jul-28-26ReiteratedCantor FitzgeraldOverweight$230 → $235
Jul-20-26InitiatedBMO CapitalOutperform$192
Jul-20-26ReiteratedH.C. WainwrightBuy$245 → $220
Jul-15-26ReiteratedWells FargoOverweight$160 → $161
Latest News
Aug-07-26
Aug-07-2611:41AM
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptakezacks.com
Aug-06-26
Aug-06-2603:05PM
Insmed Q2 Earnings Call Highlightsmarketbeat.com
02:41PM
Artisan Global Discovery Fund Q2 2026 Portfolio ActivitySeekingAlpha
11:54AM
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:31AM
Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Sayzacks.com
09:21AM
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimateszacks.com
07:00AM
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Updateprnewswire.com
Jul-29-26
Jul-29-2609:36AM
Alger Mid Cap Focus Fund Q2 2026 Portfolio ReviewSeekingAlpha
04:05AM
Insmed, Inc. $INSM Stock Holdings Reduced by Bank of Nova Scotiadefenseworld.net
Jul-27-26
Jul-27-2601:41PM
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?zacks.com
Jul-23-26
Jul-23-2607:00AM
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026prnewswire.com
Jul-22-26
Jul-22-2604:03AM
Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSMdefenseworld.net
Jul-21-26
Jul-21-2601:26PM
Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha
07:58AM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
07:41AM
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More247wallst.com
Company

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,137606364——————
Cost of Goods Sold Incl. D&A19012586——————
Gross Profit947482278——————
Selling, General and Administrative Excl. Other892701461——————
Research and Development860771598——————
Other Operating Expense1318697——————
Operating Income-818-1,177-878——————
Interest Expense818485——————
Unusual Expense
—————————
Non-Operating Income (Expense)29-1153——————
Net Income Before Taxes-869-1,272-910——————
Income Taxes654——————
Consolidated Net Income-875-1,277-914——————
Net Income From Continuing Operations-875-1,277-914——————
Net Income-875-1,277-914——————
EPS (Recurring)-4.11-6.41-5.57——————
EPS (Basic, Before Extraordinaries)-4.11-6.41-5.57——————
EPS (Diluted)-4.11-6.41-5.57——————
EBITDA-770-1,172-819——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio25.4361.4631.11——————
Gross Margin83.2979.5476.37——————
Operating Margin-71.94-194.22-241.21——————
Net Margin-76.96-210.73-251.10——————
Shares Outstanding217214164——————
Market Capitalization28,91137,24511,323——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$232.74$186.53$140.31$94.09$47.88● Close Price0.00M10.75M21.51M32.26M43.02MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Flammer Martina M.D.Chief Medical OfficerAug 06 '26Option Exercise21.2027,173576,12687,659Aug 07
Flammer Martina M.D.Chief Medical OfficerAug 06 '26Sale128.6127,1733,494,83860,486Aug 07
Lewis WilliamChair and CEOJul 23 '26Sale106.0610,7001,134,890259,058Jul 24
Lewis WilliamChair and CEOJul 23 '26Option Exercise24.9410,700266,870269,758Jul 24
Lewis WilliamChair and CEOJul 09 '26Option Exercise24.9410,699266,839269,757Jul 10
Lewis WilliamChair and CEOJul 09 '26Sale117.4010,6991,256,085259,058Jul 10
Flammer Martina M.D.Chief Medical OfficerJul 06 '26Sale109.9812,3021,352,93260,486Jul 08
Flammer Martina M.D.Chief Medical OfficerJul 06 '26Option Exercise25.8012,302317,44572,788Jul 08
Lewis WilliamChair and CEOJun 25 '26Option Exercise24.9421,398533,679280,315Jun 26
Lewis WilliamChair and CEOJun 25 '26Sale103.3221,3982,210,763258,917Jun 26
Smith Michael AlexanderChief Legal OfficerJun 22 '26Sale95.821,806173,05137,648Jun 24
Lewis WilliamChair and CEOJun 08 '26Sale94.036,515612,605258,917Jun 10
Flammer Martina M.D.Chief Medical OfficerJun 05 '26Sale103.781,858192,82360,486Jun 05
Adsett RogerChief Operating OfficerJun 03 '26Sale102.272,370242,38098,603Jun 05
Flammer Martina M.D.Chief Medical OfficerJun 03 '26Sale102.272,566262,42562,344Jun 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.